The Role of the Epidermal Growth Factor Receptor in Breast Cancer
作者： Samuel K. Chan , Mark E. Hill , William J. Gullick
DOI: 10.1007/S10911-006-9008-2
关键词:
摘要: Recent trials of drug therapy targeting the erbB receptor HER2 have met with success in breast cancer. The epidermal growth factor or EGFR is a closely related from this same family that involved cellular signal transduction and tumor cell survival. Emerging evidence indicates implicated development hormone-resistant cancer, its activity intertwined estrogen receptor. Here, role cancer reviewed, data selected clinical inhibition target are summarized.
springer.com
core.ac.uk
kent.ac.uk
researchgate.net 
sci-hub.se 参考文章(69)
William J. Gullick, David S. Salomon, The erbB family of receptors and their ligands: multiple targets for therapy. Addis International. ,(2001)
Kim Te, Murren, Erlotinib OSI/Roche/Genentech. Current opinion in investigational drugs. ,vol. 3, pp. 1385- ,(2002)
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
Anne Camirand, Mahvash Zakikhani, Fiona Young, Michael Pollak, Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells Breast Cancer Research. ,vol. 7, pp. 1- 10 ,(2005) , 10.1186/BCR1028
Sarah E Pinder, Rob I Nicholson, Ian O Ellis, John F Robertson, Roger W Blamey, Raj S Rampaul, Pete M Wencyk, Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value? Clinical Cancer Research. ,vol. 10, pp. 2578- 2578 ,(2004)
George Fountzilas, Dimitrios Pectasides, Anna Kalogera-Fountzila, Dimosthenis Skarlos, Haralambos P Kalofonos, Christos Papadimitriou, Dimitrios Bafaloukos, Stefanos Lambropoulos, Savvas Papadopoulos, Helen Kourea, Christos Markopoulos, Helen Linardou, Dimitrios Mavroudis, Evangelos Briasoulis, Nicholaos Pavlidis, Evangelia Razis, Paraskevas Kosmidis, Helen Gogas, Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Research and Treatment. ,vol. 92, pp. 1- 9 ,(2005) , 10.1007/S10549-005-0322-Y
Sufi Mary Thomas, Jennifer Rubin Grandis, Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treatment Reviews. ,vol. 30, pp. 255- 268 ,(2004) , 10.1016/J.CTRV.2003.10.003
GRAHAM CARPENTER, LLOYD KING, STANLEY COHEN, Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature. ,vol. 276, pp. 409- 410 ,(1978) , 10.1038/276409A0
Richard A. McClelland, Denise Barrow, Tracie-Ann Madden, Carol M. Dutkowski, Joanna Pamment, Janice M. Knowlden, Julia M. W. Gee, Robert I. Nicholson, Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology. ,vol. 142, pp. 2776- 2788 ,(2001) , 10.1210/ENDO.142.7.8259
H E Jones, L Goddard, J M W Gee, S Hiscox, M Rubini, D Barrow, J M Knowlden, S Williams, A E Wakeling, R I Nicholson, Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells Endocrine-related Cancer. ,vol. 11, pp. 793- 814 ,(2004) , 10.1677/ERC.1.00799